A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2004
11/25/2004	US20040234574 Compliant tissue sealants
11/25/2004	US20040234572 Preparation of sustained release pharmaceutical composition
11/25/2004	US20040234571 Injecting fluid; applying electric current; tissue engineering; drug delivery; bone reinforcement
11/25/2004	US20040234563 Emulsifier mixture
11/25/2004	US20040234557 Method for producing a bovine teat dip
11/25/2004	US20040234556 Aerosol mixture of drug particles in fluorohydrocarbon propellant
11/25/2004	US20040234538 Genetic engineered polypeptide; induce immunology response
11/25/2004	US20040234533 Antigenic compositions
11/25/2004	US20040234481 Gene transfers of angiogenic factor for skin disease
11/25/2004	US20040234474 mixture of silicone fluid , silica and drug; wound dressing; topical applying; drug delivery
11/25/2004	US20040234472 Micellar drug delivery systems for hydrophobic drugs
11/25/2004	US20040234464 Photoprotective cosmetic compositions comprising para-aminobenzalmalonate-substituted s-triazine compounds
11/25/2004	US20040234457 in situ administering into respiratory system a mixture of organic acid and metal compound
11/25/2004	US20040234456 Device for oral administration of teething drug, other drugs and other oral administration
11/25/2004	US20040232205 Lantibiotic
11/25/2004	DE20220982U1 Transdermal patch, useful for administering fentanyl or its analog through the skin, comprises a backing layer on which a reservoir containing a single phase polymeric composition is disposed
11/25/2004	DE202004011716U1 Article for preparing a vapor inhalation medium has the form of a closed, bag-like membrane containing a specified amount of salt
11/25/2004	DE10321094A1 Modular assembly for automated home preparation of baby milk produced from milk powder and hot water
11/25/2004	CA2527756A1 Immunostimulating agents
11/25/2004	CA2526933A1 Composition for maintaining organ and cell viability
11/25/2004	CA2525636A1 Hard gelatin capsule containing titanium oxide with a controlled particle size and process for producing the same
11/25/2004	CA2525468A1 Injectable depots consisting of liposomal aggregates for the delivery of active substances
11/25/2004	CA2525465A1 Topical composition for transdermal administration
11/25/2004	CA2525318A1 Bicalutamide forms, compositions, and processes thereof
11/25/2004	CA2525111A1 Drug formulations having reduced abuse potential
11/25/2004	CA2525049A1 Insoluble globin injectable implant
11/25/2004	CA2524816A1 Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
11/25/2004	CA2524634A1 Injectable liposomal depots for delivering active ingredients
11/25/2004	CA2524290A1 Mold inhibitor integrated within a matrix and method of making same
11/25/2004	CA2524228A1 Method of preparing a formulation containing a microdosed active principle
11/25/2004	CA2524097A1 Alcohol-free transdermal analgesic composition
11/25/2004	CA2523784A1 Dissolvable backing layer for use with a transmucosal delivery device
11/24/2004	EP1479766A1 Dna nanocage by self-organization of dna and process for producing the same, and dna nanotube and molecule carrier using the same
11/24/2004	EP1479432A1 Microcapsules (XXIV)
11/24/2004	EP1479402A1 Increased biocompatibility of implantable medical devices
11/24/2004	EP1479390A1 Pharmaceutical preparation containing selenite
11/24/2004	EP1479383A1 Oral sustained release pharmaceutical composition
11/24/2004	EP1479382A1 Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
11/24/2004	EP1479381A1 Pharmaceutical dosage form comprising a solid solution
11/24/2004	EP1479380A1 Use of soaps such as magnesium stearate for increasing the release of drugs
11/24/2004	EP1479379A1 Dry liposomal PVP-iodine compositions
11/24/2004	EP1479300A1 Amino acid powder and process for producing the same
11/24/2004	EP1478735A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
11/24/2004	EP1478652A2 Components for producing amphoteric liposomes
11/24/2004	EP1478605A1 Decomposable monolithic ceramic materials having an at least bimodal pore distribution and active metal centers located in the pores
11/24/2004	EP1478428A2 Device and method for delivering or withdrawing a substance through the skin
11/24/2004	EP1478406A1 Compositions for delivery of therapeutics and other materials, and methods of making and using the same
11/24/2004	EP1478405A2 Beta-homolysine conjugates and their use as transport enhancer
11/24/2004	EP1478404A1 Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
11/24/2004	EP1478403A1 Responsive microgel and methods related thereto
11/24/2004	EP1478402A1 Preparation for oxidation-sensitive compounds and method for making same
11/24/2004	EP1478399A1 Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
11/24/2004	EP1478398A1 New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
11/24/2004	EP1478394A2 Polypeptide formulation
11/24/2004	EP1478386A1 Method for drying water-borne materials
11/24/2004	EP1478382A1 Method for producing a powder inhalant containing a salt of the cgrp antagonist bibn4096
11/24/2004	EP1478378A2 Anti-allergic complex molecules
11/24/2004	EP1478372A1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
11/24/2004	EP1478353A1 Sustained release pharmaceutical composition
11/24/2004	EP1478352A1 Pharmaceutical dosage form and method for the production thereof
11/24/2004	EP1478351A1 Rapidly soluble film covering based on polyvinylalcohol-polyether graft copolymers combined with components containing hydroxyl, amide, or ester functions
11/24/2004	EP1478350A1 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core
11/24/2004	EP1478349A1 A method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
11/24/2004	EP1478348A2 Microinfusion device
11/24/2004	EP1478347A1 Dry granulated formulations of azithromycin
11/24/2004	EP1478346A1 Fast disintegrating tablets
11/24/2004	EP1478345A1 Novel pharmaceutical dosage forms and method for producing same
11/24/2004	EP1478344A2 Melt extrusion consisting of salts of active ingredients
11/24/2004	EP1478343A2 Compositions and methods for delivery of poorly water soluble drugs and methods of treatment
11/24/2004	EP1478342A1 Sterile filtered nanoparticule formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
11/24/2004	EP1478341A1 Efficient nucleic acid encapsulation into medium sized liposomes
11/24/2004	EP1478340A1 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
11/24/2004	EP1478339A1 Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
11/24/2004	EP1478338A1 Powder inhalation containing cgrp-antagonist bibn4096 and method for the production thereof
11/24/2004	EP1478337A1 System for transvaginal drug delivery
11/24/2004	EP1478328A2 Bioactive keratin peptides
11/24/2004	EP1478319A1 Granulation process
11/24/2004	EP1478314A2 Therapeutical polyanhydride compounds for drug delivery
11/24/2004	EP1478305A2 Therapeutic polyesters and polyamides
11/24/2004	EP1478276A2 Novel targeted compositions for diagnostic and therapeutic use
11/24/2004	EP1478233A2 Method for administering glp-1 molecules
11/24/2004	EP1282690B1 Isolation of precursor cells and their use for tissue repair
11/24/2004	EP1267841B1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
11/24/2004	EP1261324B1 Use of tramadol for the preparation of a medicament for the treatment of functional gastrointestinal disorders
11/24/2004	EP1221917B1 Drug delivery device
11/24/2004	EP1214078B1 Formulations for parenteral use of estramustine phosphate and amino acids
11/24/2004	EP1183231B1 Cytofectin dimers and methods of use thereof
11/24/2004	EP1176950B1 A method and a device for providing a coating on a tablet, capsule, pill or the like
11/24/2004	EP1175214B1 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/24/2004	EP1154763B1 Patch for transdermal therapy
11/24/2004	EP1148106B1 Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition
11/24/2004	EP1143962B1 Parenteral solution of propofol (2,6-diisoprophylphenol) and 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol as a solvent
11/24/2004	EP1140023B1 Integrative protein-dna cochleate formulations and methods for transforming cells
11/24/2004	EP1133286B1 Solid lipidic nanospheres suitable to a fast internalization into cells
11/24/2004	EP1115452B1 System for treating ischemia
11/24/2004	EP1100465B1 Medicinal aerosol formulations
11/24/2004	EP1079805B1 Pharmaceutical composition comprising factor viii and neutral liposomes
11/24/2004	EP1060008B1 Method of particle formation
11/24/2004	EP1027014B1 Implantable system with drug-eluting cells for on-demand local drug delivery
11/24/2004	EP1026945A4 Improved iodine antimicrobial compositions containing nonionic surfactants and halogen anions

1 ... 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 ... 2991